Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase II Trial Testing the PARP Inhibitor Niraparib in Patients With Pancreatic Cancer Harboring Deficiencies in Homologous Recombination DNA Repair

Summary

The purpose of this phase II research study is to evaluate the efficacy of niraparib as a possible treatment for pancreatic cancer.

General Information

NCT#: NCT03601923
Study ID: 18-207
Trial Phase: Phase II

Trial Sponsor: Dana-Farber Cancer Institute, Tesaro
Therapies Used in This Trial: Niraparib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search